Ventricular tachycardia future or investigational therapies: Difference between revisions
Hudakarman (talk | contribs) |
Hudakarman (talk | contribs) |
||
| Line 8: | Line 8: | ||
== Future or investigational studies == | == Future or investigational studies == | ||
In recent years, the results of pharmacologic therapy for preventing VAs are disappointing. Therapy limitations are due to variable efficacy, pro-arrhythmic effects, patient compliance, and adverse effects from long-term therapy. | In recent years, the results of [[pharmacologic]] [[therapy]] for preventing VAs are disappointing. Therapy limitations are due to variable [[efficacy]], pro-arrhythmic effects, [[patient]] [[compliance]], and [[adverse effects]] from long-term [[therapy]]. in [[patients]] with [[ICD|ICDs]], [[adjuvant]] suppressive [[therapy]] as [[amiodarone]] and [[sotalol]] have been shown to reduce the rate of recurrent VT when compared with [[beta-blockers]] or [[placebo]]. [[Pharmacologic]] [[therapy]] ([[amiodarone]] or [[sotalol]]) with or without [[adjunctive]] [[catheter ablation]] are recommended by the current guidelines to prevent VT/VF recurrence and reducing [[ICD]] shocks<ref name="pmid28721212">{{cite journal| author=Batul SA, Olshansky B, Fisher JD, Gopinathannair R| title=Recent advances in the management of ventricular tachyarrhythmias. | journal=F1000Res | year= 2017 | volume= 6 | issue= | pages= 1027 | pmid=28721212 | doi=10.12688/f1000research.11202.1 | pmc=5497814 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28721212 }}</ref> <br /> | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 21:06, 9 March 2020
|
Ventricular tachycardia Microchapters |
|
Differentiating Ventricular Tachycardia from other Disorders |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Ventricular tachycardia future or investigational therapies On the Web |
|
FDA on Ventricular tachycardia future or investigational therapies |
|
CDC onVentricular tachycardia future or investigational therapies |
|
Ventricular tachycardia future or investigational therapies in the news |
|
Blogs on Ventricular tachycardia future or investigational therapies |
|
to Hospitals Treating Ventricular tachycardia future or investigational therapies |
|
Risk calculators and risk factors for Ventricular tachycardia future or investigational therapies |
Overview
In recent years, the results of pharmacologic therapy for preventing VAs are disappointing. Therapy limitations are due to variable efficacy, pro-arrhythmic effects, patient compliance, and adverse effects from long-term therapy. in patients with ICDs, adjuvant suppressive therapy as amiodarone and sotalol have been shown to reduce the rate of recurrent VT when compared with beta-blockers or placebo. Pharmacologic therapy (amiodarone or sotalol) with or without adjunctive catheter ablation are recommended by the current guidelines to prevent VT/VF recurrence and reducing ICD shocks
Future or investigational studies
In recent years, the results of pharmacologic therapy for preventing VAs are disappointing. Therapy limitations are due to variable efficacy, pro-arrhythmic effects, patient compliance, and adverse effects from long-term therapy. in patients with ICDs, adjuvant suppressive therapy as amiodarone and sotalol have been shown to reduce the rate of recurrent VT when compared with beta-blockers or placebo. Pharmacologic therapy (amiodarone or sotalol) with or without adjunctive catheter ablation are recommended by the current guidelines to prevent VT/VF recurrence and reducing ICD shocks[1]
References
- ↑ Batul SA, Olshansky B, Fisher JD, Gopinathannair R (2017). "Recent advances in the management of ventricular tachyarrhythmias". F1000Res. 6: 1027. doi:10.12688/f1000research.11202.1. PMC 5497814. PMID 28721212.